JP2009209048A - 医薬用酸化マグネシウム - Google Patents
医薬用酸化マグネシウム Download PDFInfo
- Publication number
- JP2009209048A JP2009209048A JP2008050603A JP2008050603A JP2009209048A JP 2009209048 A JP2009209048 A JP 2009209048A JP 2008050603 A JP2008050603 A JP 2008050603A JP 2008050603 A JP2008050603 A JP 2008050603A JP 2009209048 A JP2009209048 A JP 2009209048A
- Authority
- JP
- Japan
- Prior art keywords
- magnesium oxide
- surface area
- specific surface
- activity
- bet method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 239000000395 magnesium oxide Substances 0.000 title claims abstract description 41
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 26
- 238000004438 BET method Methods 0.000 claims abstract description 22
- 239000002253 acid Substances 0.000 claims abstract description 16
- 150000007513 acids Chemical class 0.000 abstract 2
- 239000000843 powder Substances 0.000 description 17
- 239000002245 particle Substances 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 11
- -1 benzimidazole compound Chemical class 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 5
- 239000000347 magnesium hydroxide Substances 0.000 description 5
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 4
- 239000001095 magnesium carbonate Substances 0.000 description 4
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 4
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 4
- 229960004157 rabeprazole Drugs 0.000 description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
- 238000001354 calcination Methods 0.000 description 3
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229910017053 inorganic salt Inorganic materials 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229960003174 lansoprazole Drugs 0.000 description 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 3
- 235000021388 linseed oil Nutrition 0.000 description 3
- 239000000944 linseed oil Substances 0.000 description 3
- 229960000381 omeprazole Drugs 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IHHXIUAEPKVVII-APFIOPMWSA-N (2s)-2,6-diaminohexanoic acid;(2r)-2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 IHHXIUAEPKVVII-APFIOPMWSA-N 0.000 description 1
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- HKQKYZRQBYBWSZ-BMJUYKDLSA-N [(z)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-3-[[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl]disulfanyl]pent-3-enyl] dihydrogen phosphate Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(CCOP(O)(O)=O)/SSC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N HKQKYZRQBYBWSZ-BMJUYKDLSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- KKEMWYNNTBRYMR-UHFFFAOYSA-N azulene-1-sulfonic acid Chemical class C1=CC=CC=C2C(S(=O)(=O)O)=CC=C21 KKEMWYNNTBRYMR-UHFFFAOYSA-N 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- POOYFSLWYLDQMD-UHFFFAOYSA-N heptacalcium;zinc Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Zn+2] POOYFSLWYLDQMD-UHFFFAOYSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229950007395 leminoprazole Drugs 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- UDCIYVVYDCXLSX-SDNWHVSQSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(e)-5-hydroxy-3-(propyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound CCCSS\C(CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N UDCIYVVYDCXLSX-SDNWHVSQSA-N 0.000 description 1
- GFEGEDUIIYDMOX-BMJUYKDLSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(z)-3-[[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-hydroxypent-2-en-3-yl]disulfanyl]-5-hydroxypent-2-en-2-yl]formamide Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(CCO)/SSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N GFEGEDUIIYDMOX-BMJUYKDLSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- HLQVZBJJNRSVNF-UHFFFAOYSA-M potassium;azulene-1-sulfonate Chemical compound [K+].C1=CC=CC=C2C(S(=O)(=O)[O-])=CC=C21 HLQVZBJJNRSVNF-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229950007142 prosultiamine Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229950000112 serrapeptase Drugs 0.000 description 1
- 108010038132 serratiopeptidase Proteins 0.000 description 1
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 1
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229960003211 sulbutiamine Drugs 0.000 description 1
- CKHJPWQVLKHBIH-ZDSKVHJSSA-N sulbutiamine Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SS\C(CCOC(=O)C(C)C)=C(\C)N(C=O)CC1=CN=C(C)N=C1N CKHJPWQVLKHBIH-ZDSKVHJSSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229950008375 tenatoprazole Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960001385 thiamine disulfide Drugs 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- HZSAJDVWZRBGIF-UHFFFAOYSA-M thiamine(1+) monophosphate(2-) Chemical compound CC1=C(CCOP([O-])([O-])=O)SC=[N+]1CC1=CN=C(C)N=C1N HZSAJDVWZRBGIF-UHFFFAOYSA-M 0.000 description 1
- 150000003544 thiamines Chemical class 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】酸に不安定な薬剤と混合して用いられる医薬用酸化マグネシウムであって、
BET法による比表面積が20〜200m2/gで、かつ活性度が40〜200Img/gであることを特徴とする医薬用酸化マグネシウム。
【選択図】 なし
Description
BET法による比表面積が20〜200m2/gで、かつ活性度が40〜200Img/gであることを特徴とする医薬用酸化マグネシウムが提供される。
ランソプラゾール、オメプラゾール、ラベプラゾール、パントプラゾール、レミノプラゾール、テナトプラゾール、TU−199のようなベンズイミダゾール系化合物またはその塩;
イミダゾピリジン系化合物またはその塩;
セラペプターゼ、セミアルカリプロティナーゼのような消炎酵素剤;
エリスロマイシンのようなマクロライド系抗生物質;
α−トコフェノール、コハク酸トコフェノールカルシウム、コハク酸d1−α−トコフェノールカルシウム、コハク酸d−α−トコフェノールカルシウムのようなコハク酸トコフェノールまたはその塩;
塩酸チアミン、硝酸チアミン、リン酸チアミンのようなチアミン無機酸またはその塩、プロスルチアミン、フルスルチアミン、チアミンジスルフィド、リン酸チアミンジスルフィド、ピスベンチアミン、ビスプチチアミン、ビスイブチアミンのような活性型ビタミンB1誘導体またはその塩などのビタミンB1またはその塩;
アズレンスルホン酸ナトリウム、アズレンスルホン酸カリウムのようなアズレンスルホン酸塩;
イブプロフェン、イブプロフェンリシン、ケトプロフェン、フルルビプロフェン、ナプロキセンのような2−アリールプロピオン酸誘導体等
が用いられる。
酸化マグネシウム粉末の試料0.1gを下記の測定装置、前処理条件および試験条件によりBET法による比表面積を測定する。
・前処理条件:脱気しながら、105℃で1時間保持、
・試験条件:窒素吸着法により3点プロット法で測定。
最初にヨウ素13gに四塩化炭素を加えて全量を1000mLとして1N−ヨウ素四塩化炭素溶液を調製する。ヨウ化カリウム0.5gに75(W/L)%のエチルアルコールを加えて全量を100mLとして0.03N−ヨウ化カリウム溶液を調製する。また、チオ硫酸ナトリウム5水和物13および無水炭酸ナトリウム0.1gに水を加えて全量を1000mLとして0.05N−チオ硫酸ナトリウム溶液を調製する。
ここで、Nはチオ硫酸ナトリウム溶液の規定度×係数(ファクタ)である。
試料をエタノールに分散させ、超音波ホモジナイザーで前処理した後、日機装社製のマイクロトラックにより粒度分布を測定する。粒度分布の小さい粒子から積算し、50重量%の積算値の粒径を平均粒径とする。
・測定装置:筒井理化学器機社製の粉体減少度測定器(TPM−7−P)、
・試験条件:タッピング回数100回、タッピング高さ4cm、タッピング速度36回/分間。
水酸化マグネシウムNK(富田製薬株式会社商品名;平均粒径49.6μm、BET法による比表面積38.4m2/g、嵩密度0.54g/mL)および局方炭酸マグネシウム(富田製薬株式会社商品名;平均粒径11.7μm、BET法による比表面積21.9m2/g、嵩密度0.48g/mL)をそれぞれ大気雰囲気下で600℃まで昇温し、この温度を2時間保持して焼成した後、前者の焼成物と後者の焼成物とを重量比で1:3の割合で混合することにより酸化マグネシウム粉末を製造した。
軽質酸化マグネシウム粉末(富田製薬株式会社の製品)を使用した。
水酸化マグネシウムNK(富田製薬株式会社商品名;平均粒径49.6μm、BET法による比表面積38.4m2/g、嵩密度0.54g/mL)を大気雰囲気下で500℃まで昇温し、この温度を1時間保持して焼成することにより酸化マグネシウム粉末を製造した。
酸化マグネシウム粉末の試料10gを黒色プラスチック板上に置いた。ビュレットから煮アマニ油を紙料上に滴下し、へらで小円形を描くように練り、試料全体が1つの塊になった時点の煮アマニ油の滴下量を終点とし、次式(2)から吸油量を算出した。
ここで、Vは煮アマニ油の滴下量(mL)、
Wは試料の重量(10g)、
である。
酸化マグネシウム粉末の試料2gを室温の水50mLに懸濁させ、この懸濁液のpHをpH計で測定した。
実施例1〜3と、下記表1に示すBET法による比表面積、活性度、平均粒径、嵩密度、吸油量およびpHを有する比較例1の酸化マグネシウム粉末(神島化学工業社製商品名:スターマグP)とを酸に不安定な薬剤であるオメプラゾール(UNION QUIMICO社の製品)10gにそれぞれ50g混合した。
Claims (4)
- 酸に不安定な薬剤と混合して用いられる医薬用酸化マグネシウムであって、
BET法による比表面積が20〜200m2/gで、かつ活性度が40〜200Img/gであることを特徴とする医薬用酸化マグネシウム。 - BET法による比表面積が60〜150m2/gで、かつ活性度が60〜150Img/gであることを特徴とする請求項1記載の医薬用酸化マグネシウム。
- BET法による比表面積が70〜150m2/gで、かつ活性度が80〜150Img/gであることを特徴とする請求項1記載の医薬用酸化マグネシウム。
- 嵩密度が0.5g/mL以上であることを特徴とする請求項1記載の医薬用酸化マグネシウム。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008050603A JP4714929B2 (ja) | 2008-02-29 | 2008-02-29 | 酸に不安定な薬剤用安定化剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008050603A JP4714929B2 (ja) | 2008-02-29 | 2008-02-29 | 酸に不安定な薬剤用安定化剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009209048A true JP2009209048A (ja) | 2009-09-17 |
JP4714929B2 JP4714929B2 (ja) | 2011-07-06 |
Family
ID=41182563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008050603A Active JP4714929B2 (ja) | 2008-02-29 | 2008-02-29 | 酸に不安定な薬剤用安定化剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4714929B2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012124827A1 (ja) | 2011-03-17 | 2012-09-20 | 協和化学工業株式会社 | 錠剤成形用結合剤 |
WO2015128940A1 (ja) * | 2014-02-25 | 2015-09-03 | 神島化学工業株式会社 | 医薬用又は食品添加用酸化マグネシウム顆粒 |
WO2018030225A1 (ja) * | 2016-08-09 | 2018-02-15 | 神島化学工業株式会社 | 酸化マグネシウム顆粒 |
JP2020152707A (ja) * | 2019-03-22 | 2020-09-24 | キョーリンリメディオ株式会社 | 安定化されたエソメプラゾールマグネシウム水和物含有腸溶性固形製剤 |
WO2024063039A1 (ja) * | 2022-09-20 | 2024-03-28 | ロンザ株式会社 | 酸化マグネシウムを含有する遮光性ハードカプセル |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03163018A (ja) * | 1990-11-20 | 1991-07-15 | Takeda Chem Ind Ltd | 医薬固形組成物用安定化剤および安定化方法 |
JPH0753323A (ja) * | 1993-08-12 | 1995-02-28 | Nisshin:Kk | 歯牙用光硬化性充填材料 |
JPH1036290A (ja) * | 1997-04-25 | 1998-02-10 | Takeda Chem Ind Ltd | 医薬固形組成物用安定化剤および安定化方法 |
JP2001048792A (ja) * | 1998-11-26 | 2001-02-20 | Fujix Kk | 瀉下剤 |
JP2003327533A (ja) * | 2001-08-31 | 2003-11-19 | Takeda Chem Ind Ltd | 固形製剤 |
JP2006176669A (ja) * | 2004-12-22 | 2006-07-06 | Matsuda Giken Kogyo Kk | 土壌用固化材及び土壌用混合固化材 |
JP2006249052A (ja) * | 2005-03-14 | 2006-09-21 | Kyowa Hakko Kogyo Co Ltd | 酸化マグネシウム粒子 |
-
2008
- 2008-02-29 JP JP2008050603A patent/JP4714929B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03163018A (ja) * | 1990-11-20 | 1991-07-15 | Takeda Chem Ind Ltd | 医薬固形組成物用安定化剤および安定化方法 |
JPH0753323A (ja) * | 1993-08-12 | 1995-02-28 | Nisshin:Kk | 歯牙用光硬化性充填材料 |
JPH1036290A (ja) * | 1997-04-25 | 1998-02-10 | Takeda Chem Ind Ltd | 医薬固形組成物用安定化剤および安定化方法 |
JP2001048792A (ja) * | 1998-11-26 | 2001-02-20 | Fujix Kk | 瀉下剤 |
JP2003327533A (ja) * | 2001-08-31 | 2003-11-19 | Takeda Chem Ind Ltd | 固形製剤 |
JP2006176669A (ja) * | 2004-12-22 | 2006-07-06 | Matsuda Giken Kogyo Kk | 土壌用固化材及び土壌用混合固化材 |
JP2006249052A (ja) * | 2005-03-14 | 2006-09-21 | Kyowa Hakko Kogyo Co Ltd | 酸化マグネシウム粒子 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012124827A1 (ja) | 2011-03-17 | 2012-09-20 | 協和化学工業株式会社 | 錠剤成形用結合剤 |
WO2015128940A1 (ja) * | 2014-02-25 | 2015-09-03 | 神島化学工業株式会社 | 医薬用又は食品添加用酸化マグネシウム顆粒 |
US10004763B2 (en) | 2014-02-25 | 2018-06-26 | Konoshima Chemical Co., Ltd. | Magnesium oxide granules for pharmaceutical applications or for use as food additives |
WO2018030225A1 (ja) * | 2016-08-09 | 2018-02-15 | 神島化学工業株式会社 | 酸化マグネシウム顆粒 |
JPWO2018030225A1 (ja) * | 2016-08-09 | 2019-06-20 | 神島化学工業株式会社 | 酸化マグネシウム顆粒 |
JP2020152707A (ja) * | 2019-03-22 | 2020-09-24 | キョーリンリメディオ株式会社 | 安定化されたエソメプラゾールマグネシウム水和物含有腸溶性固形製剤 |
JP7321744B2 (ja) | 2019-03-22 | 2023-08-07 | キョーリンリメディオ株式会社 | 安定化されたエソメプラゾールマグネシウム水和物含有腸溶性固形製剤 |
WO2024063039A1 (ja) * | 2022-09-20 | 2024-03-28 | ロンザ株式会社 | 酸化マグネシウムを含有する遮光性ハードカプセル |
Also Published As
Publication number | Publication date |
---|---|
JP4714929B2 (ja) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0300111B1 (en) | A moisture stable solid valproic acid formulation and a method of preparing the same | |
BRPI0913379B1 (pt) | Intermediário compactado cpmpreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestão | |
Gaur et al. | Formulation and characterization of fast disintegrating tablet of aceclofenac by using sublimation method | |
JP4714929B2 (ja) | 酸に不安定な薬剤用安定化剤 | |
Malik et al. | Taste masked microspheres of ofloxacin: formulation and evaluation of orodispersible tablets | |
JP5757492B2 (ja) | 製剤用核粒子 | |
AU2008323938B2 (en) | Wet granulation using a water sequestering agent | |
JP2007522086A (ja) | プロトンポンプインヒビターを含有する固形組成物 | |
Kaur et al. | Formulation and evaluation of etoricoxib microbeads for sustained drug delivery | |
Arulkumaran et al. | Enhancement of solubility of ezetimibe by liquisolid technique | |
JP4168157B1 (ja) | 製剤用球形核粒子 | |
JP2014169318A (ja) | 製剤用崩壊型核粒子 | |
US20130059151A1 (en) | Magnesium oxide for pharmaceutical preparation | |
VenKateswaRlu et al. | Development and in-vitro Evaluation of Reconstitutable Suspension of Flucloxacillin | |
JP6367042B2 (ja) | ボリコナゾールを含む医薬組成物 | |
Odunayo et al. | Evaluation of the binding property of some binders in metronidazole tablet formulation | |
EP2117534A1 (en) | A pharmaceutical composition with atorvastatin active ingredient | |
Kumar et al. | Pharmaceutical Suspensions: An Updated Patent Review on Novel Suspending Agents and Recent Advancement | |
JP5359061B2 (ja) | 製剤用核粒子 | |
JP5585920B2 (ja) | 粒子状製剤 | |
Sharma et al. | Determination of the concentration blends of superdisintegrant for fast disintegrating tablets | |
BR112013001962B1 (pt) | composição compreendendo goma-laca e/ou um sal desta e glicolato de amido sódico | |
WO2017209216A1 (ja) | 難溶性薬物の微粒子を含有する医薬組成物の製造方法 | |
Srivastava et al. | Development and Characterization of Porous Tablets of Metoprolol Succinate for Controlled/Modulated Drug Delivery | |
Kakade et al. | Formulation and Evaluation of Floating Microspheres of Piroxicam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101019 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20101019 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20101119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110121 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110301 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110309 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4714929 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140408 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140408 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |